Baseline patient characteristics
| Parameter . | Patients (N = 54) . |
|---|---|
| Sex, n (%) | |
| Male | 32 (59) |
| Female | 22 (41) |
| Race/ethnicity, n (%) | |
| White | 39 (72) |
| Black | 12 (22) |
| Hispanic | 2 (4) |
| Other | 1 (2) |
| Median age (range), y | 61.5 (30-81) |
| CTCL subtype (per investigator) | |
| Mycosis fungoides | 38 (70) |
| Sézary syndrome | 15 (28) |
| Primary cutaneous anaplastic large cell lymphoma | 1 (2) |
| Median number of all prior therapies (range) | 6.5 (1-25) |
| Median number of systemic prior therapies (range) | 4.0 (1-11) |
| Nonsystemic therapies, n (%) | |
| Phototherapy | 27 (50) |
| Topical corticosteroids | 27 (50) |
| Radiation therapy | 26 (48) |
| Topical chemotherapy | 24 (44) |
| Topical bexarotene | 10 (19) |
| Other nonsystemic therapy | 8 (15) |
| Systemic therapies, n (%) | |
| Oral bexarotene | 37 (69) |
| Interferon | 28 (52) |
| HDAC inhibitors | 27 (50) |
| Denileukin diftitox | 14 (26) |
| Methotrexate | 13 (24) |
| mAb* | 12 (22) |
| Gemcitabine | 10 (19) |
| Other single-agent chemotherapy | 29 (54) |
| CHOP or CHOP-like regimens | 7 (13) |
| Other multiagent chemotherapy | 8 (15) |
| Extracorporeal photopheresis | 19 (35) |
| Corticosteroids | 13 (24) |
| Other systemic therapy | 8 (15) |
| Parameter . | Patients (N = 54) . |
|---|---|
| Sex, n (%) | |
| Male | 32 (59) |
| Female | 22 (41) |
| Race/ethnicity, n (%) | |
| White | 39 (72) |
| Black | 12 (22) |
| Hispanic | 2 (4) |
| Other | 1 (2) |
| Median age (range), y | 61.5 (30-81) |
| CTCL subtype (per investigator) | |
| Mycosis fungoides | 38 (70) |
| Sézary syndrome | 15 (28) |
| Primary cutaneous anaplastic large cell lymphoma | 1 (2) |
| Median number of all prior therapies (range) | 6.5 (1-25) |
| Median number of systemic prior therapies (range) | 4.0 (1-11) |
| Nonsystemic therapies, n (%) | |
| Phototherapy | 27 (50) |
| Topical corticosteroids | 27 (50) |
| Radiation therapy | 26 (48) |
| Topical chemotherapy | 24 (44) |
| Topical bexarotene | 10 (19) |
| Other nonsystemic therapy | 8 (15) |
| Systemic therapies, n (%) | |
| Oral bexarotene | 37 (69) |
| Interferon | 28 (52) |
| HDAC inhibitors | 27 (50) |
| Denileukin diftitox | 14 (26) |
| Methotrexate | 13 (24) |
| mAb* | 12 (22) |
| Gemcitabine | 10 (19) |
| Other single-agent chemotherapy | 29 (54) |
| CHOP or CHOP-like regimens | 7 (13) |
| Other multiagent chemotherapy | 8 (15) |
| Extracorporeal photopheresis | 19 (35) |
| Corticosteroids | 13 (24) |
| Other systemic therapy | 8 (15) |
CHOP indicates cyclophosphamide/doxorubicin/vincristine/prednisone; CTCL, cutaneous T-cell lymphoma; and HDAC, histone deacetylase.
Includes alemtuzumab and anti-CD4 Ab.